Evidence: hepatosplenomegaly, ascites, jaundice, low albumin, prolonged PT, and a 15-year history of chronic HBV infection.
Low albumin and prolonged PT reflect impaired hepatic protein and clotting-factor synthesis, typical of advanced cirrhosis (
Merck overview).
-
HBV infects hepatocytes, but much of the liver damage is not directly caused by the virus. It is mainly due to the host immune response.
-
Cytotoxic CD8+ T lymphocytes recognize HBV antigens on infected hepatocytes and destroy them by apoptosis and necrosis. Repeated episodes produce chronic hepatitis.
-
Persistent hepatocyte injury causes inflammation in portal tracts and at the limiting plate, called interface hepatitis. Severe continuing injury can cause bridging necrosis between portal tracts and central veins.
-
Cytokines released during chronic inflammation, especially TGF-beta, activate hepatic stellate cells in the space of Disse. These cells transform into myofibroblasts and deposit collagen, producing progressive fibrosis.
-
Fibrous septa bridge portal tracts and central veins. Surviving hepatocytes proliferate and form regenerative nodules. Thus, cirrhosis consists of diffuse fibrosis, regenerative nodules, and architectural distortion.
-
Fibrous septa and nodules compress/distort hepatic sinusoids and branches of portal veins, causing increased resistance to portal blood flow. This produces portal hypertension.
-
Portal hypertension leads to:
- Splenomegaly and hypersplenism
- Ascites
- Portosystemic collateral formation, such as esophageal varices
- Caput medusae and hemorrhoids in advanced disease
Cirrhosis causes both increased intrahepatic resistance and increased portal venous inflow, producing portal hypertension (
StatPearls review).